{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:50:11Z","timestamp":1792439411942,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1053\/j.seminhematol.2026.09.004","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:45:11Z","timestamp":1790095511000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Autologous gene therapy versus allogeneic transplantation for sickle cell disease and transfusion-dependent \u03b2-thalassemia: Choosing between 2 definitive therapies"],"prefix":"10.1053","author":[{"given":"Urvi","family":"Kapoor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2500-0958","authenticated-orcid":false,"given":"Monica","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.004_bib0001","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nature Rev Dis Primers"},{"issue":"10116","key":"10.1053\/j.seminhematol.2026.09.004_bib0002","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0140-6736(17)31822-6","article-title":"Thalassaemia","volume":"391","author":"Taher","year":"2018","journal-title":"Lancet"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.09.004_bib0003","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/bloodadvances.2021004394C","article-title":"American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation","volume":"5","author":"Kanter","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.09.004_bib0004","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3324\/haematol.2013.099747","article-title":"Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel","volume":"99","author":"Angelucci","year":"2014","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2026.09.004_sbref0005","series-title":"CASGEVY (exagamglogene autotemcel) prescribing information","year":"2026"},{"key":"10.1053\/j.seminhematol.2026.09.004_sbref0006","series-title":"LYFGENIA (lovotibeglogene autotemcel) prescribing information","year":"2023"},{"key":"10.1053\/j.seminhematol.2026.09.004_sbref0007","series-title":"ZYNTEGLO (betibeglogene autotemcel) prescribing information","year":"2022"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.09.004_bib0008","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1016\/j.ymthe.2025.04.029","article-title":"Clinical hematopoietic stem cell-based gene therapy","volume":"33","author":"John","year":"2025","journal-title":"Mol Ther"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.09.004_bib0009","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMc2313119","article-title":"Specificity of CRISPR-Cas9 editing in exagamglogene autotemcel","volume":"390","author":"Yen","year":"2024","journal-title":"New Engl J Med"},{"issue":"24","key":"10.1053\/j.seminhematol.2026.09.004_bib0010","doi-asserted-by":"crossref","first-page":"6524","DOI":"10.1182\/bloodadvances.2025016054","article-title":"Challenges and limitations of mobilization and stem cell collection for gene therapy of sickle cell disease","volume":"9","author":"Tanhehco","year":"2025","journal-title":"Blood Adv"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.09.004_bib0011","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1182\/bloodadvances.2021004232","article-title":"Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease","volume":"5","author":"Leonard","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.09.004_bib0012","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2015-03-629618","article-title":"Plerixafor+G-CSF\u2013mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy","volume":"126","author":"Karponi","year":"2015","journal-title":"Blood"},{"issue":"8041","key":"10.1053\/j.seminhematol.2026.09.004_bib0013","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41586-024-08250-x","article-title":"Long-term lineage commitment in haematopoietic stem cell gene therapy","volume":"636","author":"Calabria","year":"2024","journal-title":"Nature"},{"issue":"17","key":"10.1053\/j.seminhematol.2026.09.004_bib0014","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2017-03-772392","article-title":"At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT","volume":"130","author":"Fitzhugh","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.09.004_bib0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/bmt.2017.231","article-title":"Long-term outcome of mixed chimerism after stem cell transplantation for thalassemia major conditioned with busulfan and cyclophosphamide","volume":"53","author":"Fouzia","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.09.004_bib0016","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/bloodadvances.2024013693","article-title":"Is allogeneic transplantation for sickle cell disease still relevant in the era of gene therapy?","volume":"9","author":"Jones","year":"2025","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.004_bib0017","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2014.7192","article-title":"Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype","volume":"312","author":"Hsieh","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.004_bib0018","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1182\/hematology.2023000486","article-title":"The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally","volume":"2023","author":"Kassim","year":"2023","journal-title":"Hematology"},{"key":"10.1053\/j.seminhematol.2026.09.004_bib0019","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3389\/fimmu.2016.00507","article-title":"Immune reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Ogonek","year":"2016","journal-title":"Front Immunol"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.09.004_bib0020","doi-asserted-by":"crossref","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","article-title":"Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis","volume":"3","author":"Bartelink","year":"2016","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.004_bib0021","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30738","article-title":"Busulfan and subsequent malignancy: an evidence-based risk assessment","volume":"71","author":"Long-Boyle","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.09.004_bib0022","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.bbmt.2016.07.013","article-title":"Personalizing busulfan-based conditioning: considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee","volume":"22","author":"Palmer","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.09.004_bib0023","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1182\/bloodadvances.2025019567","article-title":"Nonmyeloablative HLA-identical sibling transplant for sickle cell disease in children: a multicenter prospective study","volume":"10","author":"Nickel","year":"2026","journal-title":"Blood Adv"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.09.004_bib0024","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2400192","article-title":"Haploidentical bone marrow transplantation for sickle cell disease","volume":"4","author":"Kassim","year":"2025","journal-title":"NEJM Evid"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.09.004_bib0025","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1182\/bloodadvances.2025017413","article-title":"Bone marrow transplantation for sickle cell disease using posttransplantation cyclophosphamide and 400 cGy TBI","volume":"10","author":"Goldenberg","year":"2026","journal-title":"Blood Adv"},{"issue":"11","key":"10.1053\/j.seminhematol.2026.09.004_bib0026","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"},{"issue":"26","key":"10.1053\/j.seminhematol.2026.09.004_bib0027","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1182\/blood.2024024519","article-title":"How I treat sickle cell disease with gene therapy?","volume":"144","author":"Sharma","year":"2024","journal-title":"Blood"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.09.004_bib0028","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1056\/NEJMoa2309676","article-title":"Exagamglogene autotemcel for severe Sickle cell disease","volume":"390","author":"Frangoul","year":"2024","journal-title":"New Engl J Med"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.09.004_bib0029","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2117175","article-title":"Biologic and clinical efficacy of LentiGlobin for sickle cell disease","volume":"386","author":"Kanter","year":"2022","journal-title":"New Engl J Med"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.09.004_bib0030","doi-asserted-by":"crossref","first-page":"325.e1","DOI":"10.1016\/j.jtct.2022.03.014","article-title":"Long-term survival after hematopoietic cell transplant for sickle cell disease compared to the United States population","volume":"28","author":"St. Martin","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.09.004_bib0031","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","article-title":"Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy\u2013a report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.09.004_bib0032","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2007-03-079665","article-title":"Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease","volume":"110","author":"Bernaudin","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.seminhematol.2026.09.004_bib0033","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/ajh.27297","article-title":"Effect of allogeneic hematopoietic stem cell transplantation on sickle cell disease-related organ complications: a systematic review and meta-analysis","volume":"99","author":"Dovern","year":"2024","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.09.004_bib0034","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/bloodadvances.2023010749","article-title":"Incidence and risk factors of pain crisis after hematopoietic cell transplantation for sickle cell disease","volume":"8","author":"Krishnamurti","year":"2024","journal-title":"Blood Adv"},{"issue":"18","key":"10.1053\/j.seminhematol.2026.09.004_bib0035","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa2309673","article-title":"Exagamglogene autotemcel for transfusion-dependent \u03b2-thalassemia","volume":"390","author":"Locatelli","year":"2024","journal-title":"New Engl J Med"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.09.004_bib0036","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa2113206","article-title":"Betibeglogene autotemcel gene therapy for non\u2013\u03b2 0 \/\u03b2 0 genotype \u03b2-thalassemia","volume":"386","author":"Locatelli","year":"2022","journal-title":"New Engl J Med"},{"issue":"10468","key":"10.1053\/j.seminhematol.2026.09.004_bib0037","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/S0140-6736(24)01884-1","article-title":"Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype \u03b2-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial","volume":"404","author":"Kwiatkowski","year":"2024","journal-title":"Lancet"},{"issue":"19","key":"10.1053\/j.seminhematol.2026.09.004_bib0038","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1182\/blood.2025029196","article-title":"Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent \u03b2-thalassemia","volume":"147","author":"Kwiatkowski","year":"2026","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.004_bib0039","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1038\/s41467-026-69756-8","article-title":"A multi-center clinical trial of allogeneic hematopoietic stem cell transplantation in transfusion-dependent thalassemia","volume":"17","author":"Liu","year":"2026","journal-title":"Nat Commun"},{"issue":"8","key":"10.1053\/j.seminhematol.2026.09.004_bib0040","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","volume":"27","author":"Kharfan-Dabaja","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.09.004_bib0041","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/17474086.2024.2423368","article-title":"Late effects of hemopoietic stem cell transplant for sickle cell disease: monitoring and management","volume":"17","author":"Goldenberg","year":"2024","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.09.004_bib0042","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1182\/blood.2021013054","article-title":"Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning","volume":"139","author":"McCurdy","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2026.09.004_bib0043","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa2109167","article-title":"Acute myeloid leukemia case after gene therapy for sickle cell disease","volume":"386","author":"Goyal","year":"2022","journal-title":"New Engl J Med"},{"issue":"12","key":"10.1053\/j.seminhematol.2026.09.004_bib0044","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1038\/s41591-023-02636-6","article-title":"Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease","volume":"29","author":"Spencer Chapman","year":"2023","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2026.09.004_bib0045","doi-asserted-by":"crossref","DOI":"10.1053\/j.seminhematol.2026.05.008","article-title":"Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies","author":"Weeks","year":"2026","journal-title":"Semin Hematol"},{"issue":"7","key":"10.1053\/j.seminhematol.2026.09.004_bib0046","doi-asserted-by":"crossref","first-page":"e575","DOI":"10.1097\/MPH.0000000000001782","article-title":"Longitudinal description of gonadal function in sickle-cell patients treated with hematopoietic stem cell transplant using alkylator-based conditioning regimens","volume":"42","author":"Elchuri","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2026.09.004_bib0047","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/s41409-022-01755-x","article-title":"Late endocrine effects after hematopoietic stem cell transplantation in children with nonmalignant diseases","volume":"57","author":"de Kloet","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1053\/j.seminhematol.2026.09.004_bib0048","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/trf.70189","article-title":"Transfusion utilization during gene therapy for sickle cell disease: a single institution experience","volume":"66","author":"Fasano","year":"2026","journal-title":"Transfusion"},{"issue":"4","key":"10.1053\/j.seminhematol.2026.09.004_bib0049","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/ajh.70200","article-title":"RBC alloimmunization impacts pediatric sickle cell disease transplant outcomes and transfusion burden: a STAR Registry report","volume":"101","author":"Inam","year":"2026","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.004_bib0050","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/bloodadvances.2024014104","article-title":"Gene therapy in transfusion-dependent non-\u03b20\/\u03b20 genotype \u03b2-thalassemia: first real-world experience of beti-cel","volume":"9","author":"Mirza","year":"2025","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2026.09.004_bib0051","unstructured":"Centers for Medicare and Medicaid Services. Cell and gene therapy access model frequently asked questions. https:\/\/www.cms.gov\/priorities\/innovation\/cgt-access-model-frequently-asked-questions."},{"issue":"2","key":"10.1053\/j.seminhematol.2026.09.004_bib0052","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7326\/M23-1520","article-title":"Gene therapy versus common care for eligible individuals with sickle cell disease in the United States","volume":"177","author":"Basu","year":"2024","journal-title":"Ann Intern Med"},{"issue":"24","key":"10.1053\/j.seminhematol.2026.09.004_bib0053","doi-asserted-by":"crossref","first-page":"6481","DOI":"10.1182\/bloodadvances.2025016701","article-title":"Improvements in health-related quality of life in patients with severe sickle cell disease after exagamglogene autotemcel","volume":"9","author":"Sharma","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"10.1053\/j.seminhematol.2026.09.004_bib0054","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70100","article-title":"Changes in the quality of life of adults with sickle cell disease following allogeneic stem cell transplantation: a mixed-methods, prospective cohort study","volume":"9","author":"Dovern","year":"2025","journal-title":"Hemasphere"},{"issue":"1","key":"10.1053\/j.seminhematol.2026.09.004_bib0055","doi-asserted-by":"crossref","first-page":"6291","DOI":"10.1038\/s41467-023-41153-5","article-title":"Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a rhesus gene therapy model","volume":"14","author":"Uchida","year":"2023","journal-title":"Nat Commun"},{"issue":"9","key":"10.1053\/j.seminhematol.2026.09.004_bib0056","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/s41591-025-03817-1","article-title":"Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial","volume":"31","author":"Agarwal","year":"2025","journal-title":"Nat Med"},{"issue":"6656","key":"10.1053\/j.seminhematol.2026.09.004_bib0057","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.ade6967","article-title":"In vivo hematopoietic stem cell modification by mRNA delivery","volume":"381","author":"Breda","year":"2023","journal-title":"Science"},{"key":"10.1053\/j.seminhematol.2026.09.004_sbref0058","series-title":"Long term follow-up after administration of human gene therapy products: guidance for industry","year":"2020"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000892?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196326000892?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T19:28:47Z","timestamp":1792438127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196326000892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":58,"alternative-id":["S0037196326000892"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.09.004","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Autologous gene therapy versus allogeneic transplantation for sickle cell disease and transfusion-dependent \u03b2-thalassemia: Choosing between 2 definitive therapies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2026.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}